Targeting polymer therapeutics to bone.
An aging population in the developing world has led to an increase in musculoskeletal diseases such as osteoporosis and bone metastases. Left untreated many bone diseases cause debilitating pain and in the case of cancer, death. Many potential drugs are effective in treating diseases but result in side effects preventing their efficacy in the clinic. Bone, however, provides a unique environment of inorganic solids, which can be exploited in order to effectively target drugs to diseased tissue. By integration of bone targeting moieties to drug-carrying water-soluble polymers, the payload to diseased area can be increased while side effects decreased. The realization of clinically relevant bone targeted polymer therapeutics depends on (1) understanding bone targeting moiety interactions, (2) development of controlled drug delivery systems, as well as (3) understanding drug interactions. The latter makes it possible to develop bone targeted synergistic drug delivery systems.
Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA.
Stewart A
SA
Low
Jindřich
J
Kopeček
D000375:Aging; D000818:Animals; D001847:Bone Diseases / Q000188:drug therapy* / Q000503:physiopathology; D001842:Bone and Bones / Q000378:metabolism; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D015195:Drug Design; D004347:Drug Interactions; D004357:Drug Synergism; D006801:Humans; D011108:Polymers / Q000737:chemistry*
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D011108:Polymers